Skip to content
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
You are currently viewing Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

  • Post author:Olly PP
  • Post published:December 30, 2016
  • Post category:Industry News
Tags: Home News, Industry Media

Read more articles

Next PostPsilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

You Might Also Like

Read more about the article Psychedelic drugs: A market poised for takeoff

Psychedelic drugs: A market poised for takeoff

June 21, 2022
Read more about the article How the COVID Pandemic Inspired Wakeful Travel’s Psychedelic Integration Journals

How the COVID Pandemic Inspired Wakeful Travel’s Psychedelic Integration Journals

November 24, 2021
Read more about the article Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

January 19, 2022

Recent Posts

  • Albert Labs Management and Board of Director Announcement
  • Expansion of Drug Discovery and a Promising Pipeline
  • Albert Labs Announces Private Placement
  • Letter of Intent (LOI) for First-In-Human studies with iNGENÅ« CRO
  • Albert Labs Provides Corporate Update

Recent Comments

    Innovative mental health medicines for patients with unmet needs

    • Legal Disclaimer
    • Privacy Policy
    • Modern Slavery Statement
    • Cookie Policy
    • Legal Disclaimer
    • Privacy Policy
    • Modern Slavery Statement
    • Cookie Policy

    © 2023 Albert Labs. All Rights Reserved

    • About
    • Team
    • Clinical Trials
    • KRN-101
    • Investing
    • Press & Updates
    • Contact
    • About
    • Team
    • Clinical Trials
    • KRN-101
    • Investing
    • Press & Updates
    • Contact
    Twitter Linkedin Youtube Envelope
    CSE:ABRT
    FSE: VB50
    CSE:ABRT
    FSE: VB50

    About Albert Labs

    We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

    If you would like support or more information around making an investment, please contact [email protected]

    Twitter Linkedin Youtube Envelope

    Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

    • This field is for validation purposes and should be left unchanged.
    Twitter
    Youtube
    Linkedin
    Instagram
    Envelope
    Twitter
    Youtube
    Linkedin
    Instagram
    Envelope

    By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.